The Autobio carbohydrate antigen 19-9 (CA19-9) chemiluminescence immunoassay (CLIA) kit is intended for the quantitative determination of CA19-9 concentration in human serum.
The CA19-9 is a carbohydrate antigen predominantly associated with gastrointestinal (GI) malignancies; pancreatic, colorectal, gastric and hepatic carcinomas. The main application of CA19-9 is in the management of diagnosed pancreatic and colorectal cancers. Immunochemically, CA 19-9 antigen is the sialated form of the blood group antigen Lewis. Clinical studies indicate that CA 19-9 assay levels have been found elevated in the serum with carcinomas of the exocrine pancreas, the colon and rectum, the stomach and lung cancer. It has been shown that a persistent elevation in CA19-9 assay value following treatment may be indicative of occult metastatic and/or residual disease. A persistently rising CA19-9 assay value may be associated with progressive malignant disease and poor therapeutic response. A declining CA19-9 assay value may be indicative of a favorable prognosis and a good response to treatment.
Increased serum CA19-9 assay values have also been observed in patients with nonmalignant conditions such as hepatitis, cirrhosis, pancreatitis, and other gastrointestinal disease. The CA 19-9 concentration should always be interpreted taking into consideration other clinical data and should not be used as a cancer screening test.
